Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.
We retrospectively evaluated 118 patients with cervical dystonia (CD) treated with botulinum toxin type A (BTX-A) for the following variables: gender, age at evaluation, age at symptom onset, disease duration, presence of head/neck pain and/or tremor, pattern of head deviation, disease progression (spreading of symptoms), etiology (primary vs. secondary), pretreatment with oral medication, and Tsui score. We investigated whether these parameters could predict the clinical outcome in a short- (<30 days) and long-term basis. On short-term treatment, there were no clinically significant differences between BTX-A responsive and non-responsive patients. On long-term treatment, however, intake of oral medication previously to BTX-A injection and higher Tsui scores were predictors of favorable response. These results suggest that the greater CD severity the more likely patients will respond to BTX-A.
Felicio
Andre C
AC
Movement Disorders Unit, Department of Neurology, Federal University of Sao Paulo, Escola Paulista de Medicina, Rua Pedro de Toledo 650, Vila Clementino, Sao Paulo, SP, 04039-002, Brazil. cf.andre@gmail.com
Godeiro-Junior
Clecio
C
de Carvalho Aguiar
Patricia
P
Borges
Vanderci
V
Silva
Sonia M A
SM
Ferraz
Henrique B
HB
D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D005544:Forecasting; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D014103:Torticollis / Q000188:drug therapy*; D016896:Treatment Outcome
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A